By Scott Meacham We have to make sure that Oklahoma innovators know that there are resources and mentoring available to them here. Twenty-five years ago, Oklahoma did not have a continuum of venture capital serving concept to growth stage companies. Now we do — thanks to assistance from the state acting through OCAST — fromRead more
News
By Scott Meacham Success of Oklahoma ventures has given me renewed admiration for the entrepreneurs who built those companies. We have had multiple successful portfolio exits in recent years — including Selexys, WeGoLook, and Alkami (originally iThryv). Just this month, Spiers New Technologies (SNT) was acquired by Cox Mobility, a division of Cox Automotive, aRead more
By Scott Meacham In entrepreneurship and venture investing, “what if” is the cornerstone of our industry. Entrepreneurship is built on promise and possibility—the willingness to imagine the unimaginable and take the risks to make it real. We all engage in the “what if” game. Oklahoma bought into “what if” in the late 1980s with theRead more
By Scott Meacham There is very big news this month for individuals and families affected by sickle cell disease (SCD). The U.S. Food and Drug Administration (FDA) has approved the first targeted treatment to reduce the frequency of pain crises in individuals living with SCD. This new drug — Adakveo® from Novartis — decreases theRead more
By Scott Meacham Copyright © 2019, The Oklahoman At i2E, we like to invest in life sciences companies. About 40 percent of our portfolio is in therapeutics, diagnostics and medical devices. We recognize the abundant opportunity for these types of startups in Oklahoma, and we have developed the staff, expertise and partnerships to commercialize technologiesRead more
By Scott Meacham Copyright © 2018, The Oklahoma Publishing Co. Anybody who’s ever heard me talk about building out Oklahoma’s innovation economy has heard me say that capital begets capital and deal flow begets deal flow. The challenge is that it takes a predictable continuum of investment capital to build a robust pipeline of startups,Read more
Scott Meacham Copyright © 2017, The Oklahoma Publishing Company There’s always a lot of discussion around pros and cons of state-sponsored venture capital funds. A recent Kauffman Foundation white paper even postulates that states should avoid state VC funds. The suggestion is that state-sponsored funds don’t match private VC funds when it comes to returnRead more
A global pharmaceutical company will pay up to $665 million for an Oklahoma City research firm that recently completed a large trial of a drug that treats pain among those with sickle cell disease.
A global pharmaceutical company will pay up to $665 million for an Oklahoma City research firm that recently completed a large trial of a drug that treats pain among those with sickle cell disease.
On March 24, OKBIO, the Greater OKC Chamber and PhRMA (representing the country’s leading biopharmaceutical research and discovery companies) are hosting a unique opportunity for Oklahomans, from doctors to patients, to learn more about the power and the working parts of clinical trials.
